Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation

Etifoxine, an 18 kDa translocator protein (TSPO) agonist for the treatment of anxiety disorders in clinic, may be able to cause acute liver injury or cytolytic hepatitis. TSPO has been demonstrated to participate in inflammatory responses in infective diseases as well as to modulate glucose and lipi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yu-Min, Sun, Hung-Yu, Chiu, Wen-Tai, Su, Hui-Chen, Chien, Yu-Chieh, Chang, Heng-Ai, Chong, Lee-Won, Chang, Hung-Chuen, Young, Kung-Chia, Bai, Chyi-Huey, Tsao, Chiung-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432734/
https://www.ncbi.nlm.nih.gov/pubmed/30984779
http://dx.doi.org/10.1155/2019/3102414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432734/
https://www.ncbi.nlm.nih.gov/pubmed/30984779
http://dx.doi.org/10.1155/2019/3102414

Ejemplares similares